Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation

Abiraterone is a selective inhibitor of androgen biosynthesis approved for the treatment of metastatic patients affected by castration-resistant or castration-sensitive prostate cancer. Intriguingly, clinical data revealed that abiraterone also delayed disease progression in bone improving bone-rela...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Michele Iuliani, Sonia Simonetti, Giulia Ribelli, Silvia Cavaliere, Bruno Vincenzi, Giuseppe Tonini, Francesco Pantano, Daniele Santini
Materialtyp: Artikel
Språk:English
Publicerad: MDPI AG 2022-09-01
Serie:Biomedicines
Ämnen:
Länkar:https://www.mdpi.com/2227-9059/10/9/2154